• Something wrong with this record ?

Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy

A. Popelová, V. Pražienková, B. Neprašová, BJ. Kasperová, L. Hrubá, M. Holubová, J. Zemenová, D. Blum, B. Železná, MC. Galas, J. Kuneš, L. Maletínská,

. 2018 ; 62 (4) : 1725-1736. [pub] -

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19028488

Obesity and type 2 diabetes mellitus (T2DM) were characterized as risk factors for Alzheimer's disease (AD) development. Subsequently, T2DM drugs, such as liraglutide, were proven to be neuroprotective compounds attenuating levels of amyloid deposits, and tau hyperphosphorylation, both hallmarks of AD. The central anorexigenic effects of liraglutide inspired us to examine the potential neuroprotective effects of palm11-PrRP31, a strong anorexigenic analog with glucose-lowering properties, in THY-Tau22 mice overexpressing mutated human tau, a model of AD-like tau pathology. Seven-month-old THY-Tau22 mice were subcutaneously infused with palm11-PrRP31 for 2 months. Spatial memory was tested before and after the treatment, using a Y-maze. At the end of the treatment, mice were sacrificed by decapitation and hippocampi were dissected and analyzed by immunoblotting with specific antibodies. Treatment with palm11-PrRP31 resulted in significantly improved spatial memory. In the hippocampi of palm11-PrRP31-treated THY-Tau22 mice, tau protein phosphorylation was attenuated at Thr231, Ser396, and Ser404, the epitopes linked to AD progression. The mechanism of this attenuation remains unclear, since the activation of those kinases most implicated in tau hyperphosphorylation, such as GSK-3β, JNK, or MAPK/ERK1/2, remained unchanged by palm11-PrRP31 treatment. Furthermore, we observed a significant increase in the amount of postsynaptic density protein PSD95, and a non-significant increase of synaptophysin, both markers of increased synaptic plasticity, which could also result in improved spatial memory of THY-Tau22 mice treated with palm11-PrRP31. Palm11-PrRP31 seems to be a potential tool for the attenuation of neurodegenerative disorders in the brain. However, the exact mechanism of its action must be elucidated.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028488
003      
CZ-PrNML
005      
20190823100952.0
007      
ta
008      
190813s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.3233/JAD-171041 $2 doi
035    __
$a (PubMed)29614684
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Popelová, Andrea $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
245    10
$a Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy / $c A. Popelová, V. Pražienková, B. Neprašová, BJ. Kasperová, L. Hrubá, M. Holubová, J. Zemenová, D. Blum, B. Železná, MC. Galas, J. Kuneš, L. Maletínská,
520    9_
$a Obesity and type 2 diabetes mellitus (T2DM) were characterized as risk factors for Alzheimer's disease (AD) development. Subsequently, T2DM drugs, such as liraglutide, were proven to be neuroprotective compounds attenuating levels of amyloid deposits, and tau hyperphosphorylation, both hallmarks of AD. The central anorexigenic effects of liraglutide inspired us to examine the potential neuroprotective effects of palm11-PrRP31, a strong anorexigenic analog with glucose-lowering properties, in THY-Tau22 mice overexpressing mutated human tau, a model of AD-like tau pathology. Seven-month-old THY-Tau22 mice were subcutaneously infused with palm11-PrRP31 for 2 months. Spatial memory was tested before and after the treatment, using a Y-maze. At the end of the treatment, mice were sacrificed by decapitation and hippocampi were dissected and analyzed by immunoblotting with specific antibodies. Treatment with palm11-PrRP31 resulted in significantly improved spatial memory. In the hippocampi of palm11-PrRP31-treated THY-Tau22 mice, tau protein phosphorylation was attenuated at Thr231, Ser396, and Ser404, the epitopes linked to AD progression. The mechanism of this attenuation remains unclear, since the activation of those kinases most implicated in tau hyperphosphorylation, such as GSK-3β, JNK, or MAPK/ERK1/2, remained unchanged by palm11-PrRP31 treatment. Furthermore, we observed a significant increase in the amount of postsynaptic density protein PSD95, and a non-significant increase of synaptophysin, both markers of increased synaptic plasticity, which could also result in improved spatial memory of THY-Tau22 mice treated with palm11-PrRP31. Palm11-PrRP31 seems to be a potential tool for the attenuation of neurodegenerative disorders in the brain. However, the exact mechanism of its action must be elucidated.
650    _2
$a zvířata $7 D000818
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hipokampus $x účinky léků $x metabolismus $x patologie $7 D006624
650    _2
$a bludiště - učení $x účinky léků $x fyziologie $7 D018782
650    _2
$a poruchy paměti $x farmakoterapie $x metabolismus $x patologie $7 D008569
650    _2
$a krátkodobá paměť $x účinky léků $x fyziologie $7 D008570
650    _2
$a myši transgenní $7 D008822
650    _2
$a neuroprotektivní látky $x farmakologie $7 D018696
650    _2
$a fosforylace $x účinky léků $7 D010766
650    _2
$a hormon uvolňující prolaktin $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D056690
650    _2
$a prostorová paměť $x účinky léků $x fyziologie $7 D065852
650    _2
$a tauopatie $x farmakoterapie $x metabolismus $x patologie $x psychologie $7 D024801
650    _2
$a proteiny tau $x metabolismus $7 D016875
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pražienková, Veronika $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
700    1_
$a Neprašová, Barbora $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic. Institute of Physiology, AS CR, Prague, Czech Republic.
700    1_
$a Kasperová, Barbora Judita $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
700    1_
$a Hrubá, Lucie $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
700    1_
$a Holubová, Martina $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
700    1_
$a Zemenová, Jana $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic. University of Chemistry and Technology, Prague, Czech Republic.
700    1_
$a Blum, David $u Université Lille, INSERM, CHU Lille, UMR - S 1172 - Jean Pierre Aubert Research Centre, Alzheimer and Tauopathies, Lille, France.
700    1_
$a Železná, Blanka $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
700    1_
$a Galas, Marie-Christine $u Université Lille, INSERM, CHU Lille, UMR - S 1172 - Jean Pierre Aubert Research Centre, Alzheimer and Tauopathies, Lille, France.
700    1_
$a Kuneš, Jaroslav $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic. Institute of Physiology, AS CR, Prague, Czech Republic.
700    1_
$a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
773    0_
$w MED00006350 $t Journal of Alzheimer's disease : JAD $x 1875-8908 $g Roč. 62, č. 4 (2018), s. 1725-1736
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29614684 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823101207 $b ABA008
999    __
$a ok $b bmc $g 1433637 $s 1066948
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 62 $c 4 $d 1725-1736 $e - $i 1875-8908 $m Journal of Alzheimer's disease $n J Alzheimers Dis $x MED00006350
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Archiving options